Plain-English translation of NCT06834230 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new medication called to see how well it works at lowering uric acid levels in people who have both high uric acid and high blood pressure. The study will compare to , an existing medication used for the same purpose. Researchers want to understand which treatment works better and is safer for patients dealing with both conditions.
Many people have both high uric acid (which can lead to gout) and high blood pressure at the same time, and current treatments don't work equally well for everyone. This trial exists to see whether this new medication could be a better option for managing both conditions together.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the new medication () or the existing medication (), starting at a low dose that gradually increases over time. You'll come in for a baseline visit within 10 weeks of enrolling, then return for check-ups over the next 24 weeks (about 6 months). During this time, researchers will monitor your uric acid levels and blood pressure to see how well the medication is working and whether you experience any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Japan
Phase
Post-approval monitoring
Sponsor
Saga University
Enrollment target
~360 participants
Started
March 2025
Primary completion
July 2027
Age range
20 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Koichi Koichi, Pr.,Dr.
Saga University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.